테스토스테론결핍증후군 남성에서 경구용 테스토스테론제와 경피용 테스토스테론 겔의 효과 비교
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박민구 | - |
dc.contributor.author | 정승민 | - |
dc.contributor.author | 안순태 | - |
dc.contributor.author | 강재일 | - |
dc.contributor.author | 신수환 | - |
dc.contributor.author | 박태용 | - |
dc.contributor.author | 배재현 | - |
dc.contributor.author | 김제종 | - |
dc.contributor.author | 문두건 | - |
dc.date.accessioned | 2021-09-08T08:30:15Z | - |
dc.date.available | 2021-09-08T08:30:15Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 2287-4208 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/118055 | - |
dc.description.abstract | Purpose: Oral testosterone undecanoate and transdermal testosterone gel are the testosterone formulas widely prescribed as hormonal replacement for tesosterone deficiency syndrome (TDS) in male patients. We evaluated the changes in serum testosterone level and the effects of these medicines. Materials and Methods: The medical records of 162 patients who were diagnosed with TDS based on serum testosterone (<2.55 ng/ml) and prescribed testosterone formula were analyzed retrospectively. In the 111 patients of group I, tablets of oral testosterone undecanoate were initially given. If the follow up serum testosterone level had not increased enough, the dosages were increased up to 6 tablets. In the 51 patients of group II, one pack of transdermal testosterone gel (5 gm) daily without dosage adjustment was prescribed. Statistical analysis was done to identify any correlations among age, initial and final aging male’s symptoms scale (AMS) score, initial, peak and final testosterone level, and duration of therapy. Results: The mean ages of group I and II were 53.4±14.5 and 55.2±11.9, respectively (p>0.05). The initial and final testosterone levels of the two groups were not significantly different. However, the peak level during treatment was significantly higher in group II (p<0.05). The maximal increment of testosterone level was also significantly higher in group II. Initially, group II reached its peak testosterone level earlier than group I. The final serum levels were not significantly different after adjustment of dosages in group I. Testosterone replacement significantly decreased the AMS scales in both groups. Conclusions: Both oral testosterone undecanoate and transdermal testosterone gel improved the serum testosterone level and symptom score for those with TDS. Transdermal testosterone gel may reach the peak serum testosterone level faster than oral testosterone undecanoate. Large prospective studies are required to assess the precise role of testosterone replacement therapy. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | 대한남성과학회 | - |
dc.title | 테스토스테론결핍증후군 남성에서 경구용 테스토스테론제와 경피용 테스토스테론 겔의 효과 비교 | - |
dc.title.alternative | Oral Testosterone Undecanoate Versus Transdermal Testosterone Gel for the Treatment of Testosterone Deficiency Syndrome: A Retrospective Comparative Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 김제종 | - |
dc.contributor.affiliatedAuthor | 문두건 | - |
dc.identifier.bibliographicCitation | The World Journal of Men's Health, v.28, no.3, pp.197 - 202 | - |
dc.relation.isPartOf | The World Journal of Men's Health | - |
dc.citation.title | The World Journal of Men's Health | - |
dc.citation.volume | 28 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 197 | - |
dc.citation.endPage | 202 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001505288 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Hypogonadism | - |
dc.subject.keywordAuthor | Testosterone | - |
dc.subject.keywordAuthor | Testosterone undecanoate | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.